News

MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development

April 14, 2022
MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development
Read more
MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development

Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

February 17, 2022
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic...
Read more
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

Modeling ischemic stroke in a triculture neurovascular unit on-a-chip

December 15, 2021
Scientists from MIMETAS introduce a new neurovascular unit on-a-chip model to study ischemic events in the human brain.
Read more
Modeling ischemic stroke in a triculture neurovascular unit on-a-chip

Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

December 10, 2021
- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met - The triplet combination sho...
Read more
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

InteRNA Technologies Announces U.S. FDA Clearance of IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3 in Patients with Advanced Solid Tumors

December 02, 2021
IND approval enables clinical trial advancement and enrollment of dose expansion cohorts in the US
Read more
InteRNA Technologies Announces U.S. FDA Clearance of  IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3 in Patients with Advanced Solid Tumors

InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board

October 19, 2021
-- Adding deep preclinical and clinical immuno-oncology expertise to expand InteRNA's preclinical pipeline and accelerate clini...
Read more
InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board

InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board

October 12, 2021
Appointment of Andrea van Elsas as a new member of the Company's Supervisory Board.
Read more

Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A

October 07, 2021
Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A
Read more
Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A

Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

October 07, 2021
- Tumor shrinkage and partial responses observed in patients with advanced head and neck squamous cell carcinoma (HNSCC) treate...
Read more
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Sapreme Presents Promising New Preclinical Data at 17th Annual Meeting of Oligonucleotide Therapeutics Society

September 27, 2021
Sapreme Presents Promising New Preclinical Data at 17th Annual Meeting of Oligonucleotide Therapeutics Society
Read more
Sapreme Presents Promising New Preclinical Data at 17th Annual Meeting of Oligonucleotide Therapeutics Society

ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b

September 14, 2021
Fast Track designation for the treatment of recurrent and metastatic HPV16-positive oropharyngeal cancer to improve survival an...
Read more
ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b

ORCA Therapeutics B.V. to Start Repeat-Dosing in Phase 1/2a Study of ORCA-010 in TreatmentNaïve Prostate Cancer Patients.

September 07, 2021
ORCA Therapeutics B.V. is pleased to announce the successful completion of the single-dose escalation cohorts of the Phase I/II...
Read more
ORCA Therapeutics B.V. to Start Repeat-Dosing in Phase 1/2a Study of ORCA-010 in TreatmentNaïve Prostate Cancer Patients.

Stepping to the Exit - Publication in Nature Biotechnology

August 27, 2021
Building a business. Stepping to the exit.
Read more

A Microfluidic 3D Endothelium-on-a-Chip Model to Study Transendothelial Migration of T Cells in Health and Disease

August 02, 2021
Scientists from MIMETAS and Merck introduce an assay to study 3D T cell dynamics under flow and in real-time using a high-throu...
Read more
A Microfluidic 3D Endothelium-on-a-Chip Model to Study Transendothelial Migration of T Cells in Health and Disease

ISA, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline

July 20, 2021
Grant accelerates clinical development of immunotherapy to treat chronic hepatitis B virus infection
Read more
ISA, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline

ISA Pharmaceuticals announces successful closing of EUR 26 million funding round

July 13, 2021
The proceeds of this round will be used to advance the lead product ISA101b towards first marketing authorization as well as to...
Read more
ISA Pharmaceuticals announces successful closing of EUR 26 million funding round

MIMETAS and Roche enter into a collaboration to develop human disease models for drug development

July 06, 2021
- Risk-sharing alliance on tailor-made phenotypic models for IBD and HBV - Upfront payment and milestone payments for MIMETAS...
Read more
MIMETAS and Roche enter into a collaboration to develop human disease models for drug development

Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing compound SPT001 to enable superior targeted delivery of oligonucleotides.

June 10, 2021
Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing...
Read more
Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing compound SPT001 to enable superior targeted delivery of oligonucleotides.

MIMETAS wins Deshima award for Dutch-Japanese business relations

June 07, 2021
MIMETAS wins Deshima award for Dutch-Japanese business relations.
Read more
MIMETAS wins Deshima award for Dutch-Japanese business relations

Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)

June 04, 2021
- 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data...
Read more
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
1 2 3 4 Next

Home > News > Archive

© 2022 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds